tolvaptan has been researched along with Psychoses in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Filmyer, DM; Geboy, AG; Josiassen, RC; Shaughnessy, RA | 1 |
| Siegel, AJ | 1 |
| Audino, B; Curtis, J; Filmyer, DM; Josiassen, RC; Shaughnessy, RA; Skuban, N | 1 |
| Curtis, JL; Czerwiec, F; Filmyer, DM; Geboy, AG; Josiassen, RC; Ouyang, J; Shaughnessy, RA; Skuban, N | 1 |
1 review(s) available for tolvaptan and Psychoses
| Article | Year |
|---|---|
Tolvaptan: a new tool for the effective treatment of hyponatremia in psychotic disorders.
Topics: Antidiuretic Hormone Receptor Antagonists; Antipsychotic Agents; Benzazepines; Comorbidity; Humans; Hyponatremia; Inappropriate ADH Syndrome; Prevalence; Psychotic Disorders; Tolvaptan | 2010 |
1 trial(s) available for tolvaptan and Psychoses
| Article | Year |
|---|---|
Vaptans: a potential new approach for treating chronic hyponatremia in psychotic patients.
Topics: Administration, Oral; Adult; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Chronic Disease; Dose-Response Relationship, Drug; Drug-Related Side Effects and Adverse Reactions; Humans; Hyponatremia; Long-Term Care; Male; Middle Aged; Psychotic Disorders; Sodium; Tolvaptan; Treatment Outcome | 2012 |
2 other study(ies) available for tolvaptan and Psychoses
| Article | Year |
|---|---|
Reconsidering chronic hyponatremia in psychosis.
Topics: Antidiuretic Hormone Receptor Antagonists; Benzazepines; Chronic Disease; Diagnosis, Differential; Humans; Hyponatremia; Natriuretic Agents; Patient Selection; Psychotic Disorders; Severity of Illness Index; Sodium; Tolvaptan; Treatment Outcome; Water-Electrolyte Balance | 2013 |
Is urine concentration a reliable biomarker to guide vaptan usage in psychiatric patients with symptomatic hyponatremia?
Topics: Antidiuretic Hormone Receptor Antagonists; Benzazepines; Biomarkers; Humans; Hyponatremia; Psychotic Disorders; Sodium; Tolvaptan | 2015 |